Article

Vitamin D Panacea No More

Author(s):

Vitamin D supplementation may not protect the heart from major adverse cardiovascular events, myocardial infarction, stroke or cardiovascular disease mortality, finds a study published in JAMA Cardiology.

Vitamine D cardiovascular health

(©RSzatkowski,Shutterstock.com)

Vitamin D supplementation may not protect the heart from major adverse cardiovascular events, myocardial infarction, stroke or cardiovascular disease mortality, finds a study published in JAMA Cardiology.

This was a meta-analysis of 21 randomized clinical trials of 41,669 patients (mean age 65.8 years, 74 percent female) who received vitamin D supplementation of at least one year and 41,622 who received a placebo. The primary outcome was the occurrence of major adverse cardiovascular events. Myocardial infarction, stroke or cerebrovascular accident, CVD mortality, and all-cause mortality were the secondary end points.

Vitamin D supplementation was not associated with reduced major adverse cardiovascular events, nor was it associated with the occurrence of myocardial infarction, stroke, CVD mortality or all-cause mortality.

The findings contradict those of previous observational studies that suggested vitamin D supplementation could reduce the risk of major adverse cardiac events, myocardial infarction, stroke or cardiovascular disease mortality.

"Although observational studies have suggested that low serum levels of 25-hydroxyvitamin D are associated with an increased risk of CVD events, the effects of vitamin D supplementation did not appear to vary according to baseline 25-hydroxyvitamin D levels in either the Vitamin D and Omega-3 Trial (VITAL)or Vitamin D Assessment (VIDA) trials," wrote researchers who were led by Mahmoud Barbarawi, M.D., Michigan State University.

In a commentary that was published in the same issue of JAMA Cardiology, Arshed A. Quyyumi, M.D., and Ibhar Al Mheid, M.D., suggested that vitamin D recommendations should be reconsidered.

“Widespread fascination with vitamin D as a panacea for most illnesses, including cardiovascular diseases (CVD), is responsible for nearly a 100-fold increase in vitamin D testing and oral supplementation over the last decade, largely in populations at low risk for vitamin D deficiency.1 Assessment of vitamin D levels is the fifth most commonly ordered laboratory test,” they wrote. “The popularity of vitamin D supplementation is at least partly owing to the misinterpretation of impressive epidemiologic associations between vitamin D status and a breadth of health metrics, leading to a potentially flawed assumption of causality.”

REFERENCE

Mahmoud Barbarawi, MD; Babikir Kheiri, MD; Yazan Zayed, MD; et al. "Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials." JAMA Cardiology. June 19, 2019. DOI:10.1001/jamacardio.2019.1870

Arshed A. Quyyumi, MD; Ibhar Al Mheid, MD. "The Demise of Vitamin D for Cardiovascular Prevention." JAMA Cardiology. June 19, 2019. DOI:10.1001/jamacardio.2019.1906

 

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
Orly Vardeny, PharmD | Credit: JACC Journals
© 2024 MJH Life Sciences

All rights reserved.